Orforglipron and retatrutide are two investigational weight loss drugs from Eli Lilly — one oral, one injectable. Here's how they compare in trials.
Orforglipron and retatrutide are two investigational weight loss medications from Eli Lilly, both studied for obesity and type 2 diabetes. The biggest practical difference is the route: orforglipron is an oral pill taken once daily, while retatrutide is a once-weekly injection. Neither drug is FDA-approved for chronic weight management as of this writing, so both remain experimental options available mainly through clinical trials.
What Is Orforglipron?
Orforglipron is an oral, non-peptide GLP-1 receptor agonist. Because it is a small molecule rather than a peptide, it can survive the digestive tract and be swallowed as a tablet instead of injected.
In Phase 2 research, adults with obesity taking orforglipron lost roughly 9% to 15% of body weight over about 36 weeks, depending on dose. Later Phase 3 results reported by the manufacturer showed comparable or larger reductions at higher doses, along with improvements in A1C and other cardiometabolic markers.
- Route: oral tablet, once daily
- Mechanism: GLP-1 receptor agonist only
- Developer: Eli Lilly
- Status: investigational; not approved for US use
What Is Retatrutide?
Retatrutide is a once-weekly injectable triple agonist that targets GLP-1, GIP, and glucagon receptors at the same time. That third glucagon arm is the main feature that separates it from semaglutide and tirzepatide.
In a Phase 2 trial published in the New England Journal of Medicine, adults with obesity who stayed on retatrutide for 48 weeks lost an average of about 24% of body weight at the highest dose. That is among the largest reductions reported for any obesity drug candidate to date.
Orforglipron vs Retatrutide: Side-by-Side Comparison
| Feature | Orforglipron | Retatrutide |
|---|---|---|
| Route | Oral tablet | Subcutaneous injection |
| Dosing frequency | Once daily | Once weekly |
| Receptors targeted | GLP-1 | GLP-1, GIP, glucagon |
| Developer | Eli Lilly | Eli Lilly |
| Trial weight loss (Phase 2) | About 9%–15% over ~36 weeks | About 24% over 48 weeks at top dose |
| Common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea, constipation, higher resting heart rate |
| FDA status | Not approved | Not approved |
How Their Mechanisms Differ
GLP-1 receptor activation is the shared foundation of both drugs. It reduces appetite, slows how quickly the stomach empties, and improves insulin release when blood sugar is high.
Retatrutide adds GIP and glucagon activity on top of that. Glucagon receptor agonism appears to raise energy expenditure, which may explain part of its larger weight loss numbers. It may also explain why trial participants on retatrutide sometimes show an increase in resting heart rate.
Side Effects, Cautions, and Open Questions
Both drugs are gastrointestinal-heavy in trials. Nausea, vomiting, diarrhea, and constipation are the most frequently reported complaints, and they are the main reason people stop treatment early. Orforglipron's pill form has not eliminated those effects; absorption also appears sensitive to food and fluid intake, which matters for consistent dosing.
Anyone weighing these candidates against current options should understand the difference between retatrutide and semaglutide. Semaglutide has years of post-approval safety data behind it, while retatrutide is still working through late-stage trials.
Because retatrutide is investigational, there is no established human safety data on retatrutide and alcohol, on retatrutide and pregnancy, or on how it interacts with most prescription medications. The same is true for orforglipron. People who are pregnant, breastfeeding, or managing conditions such as gastroparesis should not use these compounds outside a supervised trial.
Heart rate is another reason for caution. Glucagon activity can nudge resting heart rate upward, which is part of why researchers pay attention to retatrutide and pots — people with postural orthostatic tachycardia syndrome may be especially sensitive to that effect.
Is Stacking or Combining Them an Option?
No. There is no clinical data on combining orforglipron and retatrutide, and researchers have not studied stacking tirzepatide and retatrutide either. Pairing two GLP-1-based drugs would likely amplify gastrointestinal side effects without any proven added benefit.
The same logic applies to gray-market questions about whether you can mix mots-c and retatrutide together. No trials support that combination, and unregulated peptides carry real risks around purity, dosing accuracy, and contamination.
What Comes Next
Both drugs are in late-stage development, and each offers a different kind of advantage. Orforglipron's selling point is convenience: a pill removes needles, cold-chain shipping, and injection training. Retatrutide's selling point is potency, since its Phase 2 weight loss numbers exceed anything approved so far.
Until regulators finish reviewing the data, the honest answer for anyone asking about orforglipron and retatrutide is that both look promising but remain unproven for general use. Anyone considering either should talk with a healthcare professional about approved options first, and should be skeptical of any seller claiming to offer them today.
RELATED PEPTIDE TOPICLY-3437943Frequently Asked Questions
Is orforglipron or retatrutide FDA-approved?
No. As of this writing, neither orforglipron nor retatrutide is FDA-approved for weight loss or any other indication in the United States. Both are investigational and have only been available to participants in clinical trials. Approved alternatives such as semaglutide and tirzepatide are the options with established regulatory clearance.
Which causes more weight loss, orforglipron or retatrutide?
In Phase 2 trials, retatrutide produced larger average weight loss — roughly 24% of body weight over 48 weeks at the highest dose — compared with about 9% to 15% for orforglipron over roughly 36 weeks. These are cross-trial comparisons, not head-to-head results, so differences in study design, duration, and dose escalation make direct comparisons imperfect.
Can you take orforglipron and retatrutide together?
There is no clinical research on combining orforglipron and retatrutide, and doing so outside a trial is not recommended. Both drugs act on GLP-1 receptors, so stacking them would likely worsen nausea, vomiting, and other gastrointestinal effects without a documented benefit. Anyone interested in combination therapy should discuss it with a licensed healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.